Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman Sells 4,284 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman sold 4,284 shares of Tango Therapeutics stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $12,809.16. Following the sale, the chief financial officer now owns 154,232 shares of the company’s stock, valued at approximately $461,153.68. This represents a 2.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tango Therapeutics Stock Down 2.7 %

Shares of TNGX stock opened at $3.26 on Friday. The stock’s fifty day simple moving average is $3.14 and its 200 day simple moving average is $6.12. Tango Therapeutics, Inc. has a one year low of $2.59 and a one year high of $12.89.

Hedge Funds Weigh In On Tango Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Quest Partners LLC boosted its stake in Tango Therapeutics by 1,448.4% in the third quarter. Quest Partners LLC now owns 10,885 shares of the company’s stock worth $84,000 after purchasing an additional 10,182 shares in the last quarter. SG Americas Securities LLC acquired a new position in Tango Therapeutics in the third quarter worth $151,000. China Universal Asset Management Co. Ltd. boosted its stake in Tango Therapeutics by 64.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $159,000 after purchasing an additional 8,055 shares in the last quarter. Catalina Capital Group LLC acquired a new position in Tango Therapeutics in the fourth quarter worth $82,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Tango Therapeutics by 8.1% in the second quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company’s stock worth $253,000 after purchasing an additional 2,218 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TNGX. Guggenheim cut their price objective on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Tango Therapeutics in a research report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a research report on Thursday, December 5th. Finally, B. Riley lowered their price objective on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $13.14.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.